Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study
AF Leuchter, IA Cook, LB Marangell, WS Gilmer… - Psychiatry …, 2009 - Elsevier
Patients with Major Depressive Disorder (MDD) may not respond to antidepressants for 8
weeks or longer. A biomarker that predicted treatment effectiveness after only 1 week could …
weeks or longer. A biomarker that predicted treatment effectiveness after only 1 week could …
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis
F Hieronymus, A Lisinski, S Nilsson… - The Lancet Psychiatry, 2019 - thelancet.com
Background Reports claiming that antidepressants are effective only in patients with severe
depression have affected treatment guidelines but these reports usually use a disputed …
depression have affected treatment guidelines but these reports usually use a disputed …
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial
ES Friedman, LL Davis, S Zisook… - European …, 2012 - Elsevier
The objective of this manuscript is to report associations between baseline depressive
severity and (1) baseline sociodemographic and clinical characteristics,(2) treatment …
severity and (1) baseline sociodemographic and clinical characteristics,(2) treatment …
Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial
Background Approximately 50% of patients with major depressive disorder (MDD) do not
respond optimally to antidepressant treatments. Given this is a large proportion of the patient …
respond optimally to antidepressant treatments. Given this is a large proportion of the patient …
Prognostic subgroups for citalopram response in the STAR* D trial
E Jakubovski, MH Bloch - The Journal of clinical psychiatry, 2014 - psychiatrist.com
Objective: Few data exist to help clinicians predict likelihood of treatment response in
individual patients with major depressive disorder (MDD). Our aim was to identify subgroups …
individual patients with major depressive disorder (MDD). Our aim was to identify subgroups …
Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression
BR Godlewska, M Browning, R Norbury… - Translational …, 2016 - nature.com
Antidepressant treatment reduces behavioural and neural markers of negative emotional
bias early in treatment and has been proposed as a mechanism of antidepressant drug …
bias early in treatment and has been proposed as a mechanism of antidepressant drug …
Short-term effects of escitalopram on regional brain function in first-episode drug-naive patients with major depressive disorder assessed by resting-state functional …
L Wang, K Li, Q Zhang, Y Zeng, W Dai, Y Su… - Psychological …, 2014 - cambridge.org
BackgroundMost knowledge regarding the effects of antidepressant drugs is at the receptor
level, distal from the nervous system effects that mediate their clinical efficacy. Using …
level, distal from the nervous system effects that mediate their clinical efficacy. Using …
Toward a neuroimaging treatment selection biomarker for major depressive disorder
CL McGrath, ME Kelley, PE Holtzheimer… - JAMA …, 2013 - jamanetwork.com
Importance Currently, fewer than 40% of patients treated for major depressive disorder
achieve remission with initial treatment. Identification of a biological marker that might …
achieve remission with initial treatment. Identification of a biological marker that might …
Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram
GI Papakostas, K Larsen - European archives of psychiatry and clinical …, 2011 - Springer
The purpose of this analysis was to explore the potential role of anxious MDD as a treatment
predictor and moderator in major depressive disorder (MDD) using a large escitalopram …
predictor and moderator in major depressive disorder (MDD) using a large escitalopram …
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major …
AF Leuchter, IA Cook, WS Gilmer, LB Marangell… - Psychiatry …, 2009 - Elsevier
We examined the Antidepressant Treatment Response (ATR) index as a predictor of
differential response and remission to escitalopram, bupropion, or a combination of the two …
differential response and remission to escitalopram, bupropion, or a combination of the two …